Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

PCI on Native Arteries or Saphenous Vein Grafts: Which Has Better Prognosis?

New revascularization after coronary artery bypass graft (CABG) is often needed, be it because of severe bridge lesion, intimal hyperplasia, thrombosis, atherosclerosis, or native vessel lesion progression.

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

We therefore need to determine the best revascularization strategy, namely native or graft percutaneous intervention, venous or arterial, or repeat surgery, with the risk it entails. 

There is no clear evidence to support either bridge or native graft PCI as the best option.  

With this question in mind, the study looked at 435 PCI procedures performed on CABG patients. Target lesions were 235 on native coronary arteries (54% NA) and the remaining 200 on vein bridges (46% SVG).

There were no differences between populations. Mean age was 70, 14% were women, 40% diabetic, 14% had kidney failure, 1% were on dialysis, 70% had prior MI and 25% prior PCI. Ventricular ejection fraction ≤40% was present in 25%. There was a difference in favor of the SVG group in years between CABG and PCI (12 years vs. 10 years p=0.002) and the need for emergency procedures. (60% vs. 49% p=0.021).

Read also: Hand Function after Distal Radial Access: Is it Safe?

52% of procedures had femoral access and there was no difference in treated vessel, be it native or graft. There were differences in number of stents (higher in NA group) and diameter (larger in SVG patients) There were no differences in length.

SVG patients received more BMS and final TIMI 3 flow was higher in the NA group. In addition, the presence of no reflow was higher in the SVG group (10% vs. 0.4% p<0.001).

Populations were matched using propensity score, which left 167 patients in each group. 

Read also: FFR and IFR: Are We Talking About the Same Thing?

At 12-month followup, MACE was higher in the SVG group, driven by MI and new revascularization.

At multivariable analysis, SVG were predictors of MACE (hazard ratio [HR] 1.725, 95% confidence interval [CI] 1.049–2.837), driven by the need for new revascularization (HR 2.218, 95% CI 1.193–4.122) and MI (HR 2.248, 95% CI 1.220–4.142), with no difference in mortality at 12 months.

Conclusion

Compared against graft PCI, saphenous vein graft PCI is associated to higher MACE incidence at one year driven mainly by MI and revascularization.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: One-year outcomes of percutaneous coronary intervention in native coronary arteries versus saphenous vein grafts in patients with prior coronary artery bypass graft surgery.

Reference: Amr Abdelrahman, et al. Cardiology Journal 2022, Vol. 29, No. 3, 396–404. DOI: 10.5603/CJ.a2020.0131.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...